SGLT2 Inhibitors Reduce Gout Risk in Diabetes — GLP-1 Drugs Do Not
SGLT2 inhibitors reduced gout incidence by 17–25% in people with type 2 diabetes, while GLP-1 drugs showed no effect on gout rates.
Quick Facts
What This Study Found
SGLT2 inhibitors with metformin reduced gout incidence by 25% compared to metformin alone (HR 0.75, p < 0.0001). SGLT2 inhibitors with insulin reduced gout by 17% versus insulin alone (HR 0.83, p < 0.0001).
GLP-1 receptor agonists showed no significant difference in gout incidence versus either metformin or insulin controls.
When SGLT2 inhibitors were compared directly to GLP-1 drugs, they had lower gout rates in both the metformin group (HR 0.77, p < 0.0001) and the insulin group (HR 0.82, p < 0.0001).
Key Numbers
- Metformin control: 1,111,449 patients
- SGLT2i + metformin: 101,706 patients
- GLP-1 + metformin: 110,180 patients
- Insulin control: 1,398,066 patients
- SGLT2i + metformin vs metformin: HR 0.75 (95% CI 0.69-0.82, p < 0.0001)
- SGLT2i + insulin vs insulin: HR 0.83 (95% CI 0.74-0.92, p < 0.0001)
- SGLT2i vs GLP-1 (metformin users): HR 0.77 (p < 0.0001)
- SGLT2i vs GLP-1 (insulin users): HR 0.82 (p < 0.0001)
How They Did This
Researchers conducted a cohort study using the TriNetX federated database, an international electronic health records network. They included patients started on metformin or insulin, with or without an SGLT2 inhibitor or GLP-1 drug, at least 2 years before the analysis date. Groups were propensity score matched (1:1) for 26 characteristics. They tracked gout, all-cause mortality (positive control), and herpes zoster (negative control) over 5 years.
Why This Research Matters
Gout is common in type 2 diabetes. SGLT2 inhibitors lower uric acid levels (the chemical that causes gout) as part of how they work. This study provides large-scale real-world evidence that this biochemical effect translates to fewer actual gout episodes. For patients with both diabetes and gout risk, this could tip the scale toward SGLT2 inhibitors.
The Bigger Picture
SGLT2 inhibitors lower uric acid as part of how they work. This study provides large-scale real-world evidence that this biochemical effect translates to fewer actual gout episodes, giving them an advantage for patients with both diabetes and gout risk.
What This Study Doesn't Tell Us
This is an observational database study with propensity score matching, not a randomized trial. Residual confounding is possible despite matching for 26 variables. Gout diagnosis in electronic health records may be inconsistent. The TriNetX database may not represent all populations equally. The study compared drug additions rather than head-to-head monotherapy.
Questions This Raises
- ?Should patients with diabetes and gout be preferentially prescribed SGLT2 inhibitors?
- ?Why don't GLP-1 drugs reduce gout despite their weight loss effects?
Trust & Context
- Key Stat:
- HR 0.75 for gout with SGLT2i Adding an SGLT2 inhibitor to metformin reduced gout incidence by 25% over 5 years in the largest study of its kind
- Evidence Grade:
- Rated moderate: massive observational study with propensity score matching provides strong real-world evidence, but it is not a randomized trial.
- Study Age:
- Published in 2024 using data from the TriNetX international database with 5-year follow-up.
- Original Title:
- SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum.
- Published In:
- Clinical therapeutics, 46(11), 835-840 (2024)
- Authors:
- Preston, Frank G, Anson, Matthew(5), Riley, David R(4), Ibarburu, Gema H, Henney, Alexander, Lip, Gregory Y H, Cuthbertson, Daniel J, Alam, Uazman, Zhao, Sizheng S
- Database ID:
- RPEP-09091
Evidence Hierarchy
Frequently Asked Questions
Which diabetes drugs reduce gout?
SGLT2 inhibitors (like empagliflozin and dapagliflozin) reduce gout risk by 17–25%. GLP-1 drugs, DPP-4 inhibitors, metformin, and insulin do not.
Why do SGLT2 inhibitors lower gout risk?
They increase uric acid excretion through the kidneys, lowering blood uric acid levels. Since high uric acid causes gout, this biochemical effect translates to fewer gout attacks.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09091APA
Preston, Frank G; Anson, Matthew; Riley, David R; Ibarburu, Gema H; Henney, Alexander; Lip, Gregory Y H; Cuthbertson, Daniel J; Alam, Uazman; Zhao, Sizheng S. (2024). SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum.. Clinical therapeutics, 46(11), 835-840. https://doi.org/10.1016/j.clinthera.2024.06.021
MLA
Preston, Frank G, et al. "SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum.." Clinical therapeutics, 2024. https://doi.org/10.1016/j.clinthera.2024.06.021
RethinkPeptides
RethinkPeptides Research Database. "SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce In..." RPEP-09091. Retrieved from https://rethinkpeptides.com/research/preston-2024-sglt2-inhibitors-but-not
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.